Ligand Pharmaceuticals LGND Accrued Royalties (Current)
Accrued Royalties (Current) at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedRoyaltiesCurrentAndNoncurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's accrued royalties (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's accrued royalties (current)?
- Ligand Pharmaceuticals (LGND) reported accrued royalties (current) of $18.03M in Q1 2026.
- How has Ligand Pharmaceuticals's accrued royalties (current) changed year-over-year?
- Ligand Pharmaceuticals's accrued royalties (current) increased by 136.2% year-over-year, from $7.63M to $18.03M.
- What is the long-term trend for Ligand Pharmaceuticals's accrued royalties (current)?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's accrued royalties (current) has grown at a 87.8% compound annual growth rate (CAGR), from $693K to $16.2M.